// App-Quantinova.ai

6049.0 : Phase I/II trial assessing hydroxychloroquine and itraconazole in women with advanced platinum-resistant epithelial ovarian cancer (EOC) (HYDRA-01).

Researchers

Presenter

  • Ainhoa Madariaga

Principal Investigators

  • Stefano Marastoni

  • Ilaria Colombo

  • Victoria Mandilaras

  • Michael Cabanero

  • Jeffrey Bruce

  • Swati Garg

  • Lisa Wang

  • Sarbjot Gill

  • Neesha C. Dhani

  • Valerie Bowering

  • Xuan Li

  • Amit M. Oza

  • Anthony M. Joshua

  • Stephanie Lheureux

Medical Centers

  • Princess Margaret Cancer Centre University Health Network, Toronto, Ontario, Canada

  • Princess Margaret Cancer Center, Toronto, ON, Canada

  • Department of Medical Oncology, McGill University Health Center, Montreal, QC, Canada

  • Universtiy Health Network, Toronto, ON, Canada

  • Universtiy Health Network, Toronto, ON, Canada

  • Department of Biostatistics, Princess Margaret Cancer Centre, Toronto, ON, Canada

  • Princess Margaret Cancer Centre, University Health Network and University of Toronto, Toronto, Ontario, Canada.

  • Princess Margaret Hospital, Toronto, ON, Canada

Locations

  • Canada

Companies

  • N/A

Study Components

Therapeutic Area

  • Oncology (ONC)

Disease

  • N/A

Biomarkers

  • N/A

Drug/Treatment

  • Hydroxychloroquine

  • Itraconazole

  • Canadiol

  • Isoniazid

Outcome

  • N/A

Study Design

  • Dose Escalation

Phase

  • NA

Study Id's

  • NCT03081702

Sponsors

  • N/A

Result

  • N/A

Copyright © 2026. QuantiNova All rights reserved